the cytisinicline, a cytisinicline - based smoking cessation aid, is a promising drug for smoking cessation. the cytisinicline dose is modified to 12 weeks in order to match the cytisinicline dosing schedule. the cytisinilicline dose is modified to 12 weeks in order for cytisinicline to be easier for subjects and potentially result in better smoking cessation rates than the current market leader with Chantix. the upcoming cytisinicline phase 3 trial is a multicenter, double blind randomized, placebo - controlled phase 3 trial that will randomlyize 750 adults with intention to quit smoking. the non -clinical data required by FDA to commence the upcoming phase 3 trial has now been submitted for FDA review. the first phase 3 trial will commence in the fourth quarter of 2020 with covid-19 permitting.